- Home
- CANF vs SNX Comparison
CANF vs SNX Comparison
Compare CANF & SNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- SNX
- Stock Information
- Founded
- CANF 1994
- SNX 1980
- Country
- CANF Israel
- SNX United States
- Employees
- CANF N/A
- SNX N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- SNX Retail: Computer Software & Peripheral Equipment
- Sector
- CANF Health Care
- SNX Technology
- Exchange
- CANF Nasdaq
- SNX Nasdaq
- Market Cap
- CANF 7.9M
- SNX N/A
- IPO Year
- CANF N/A
- SNX 2003
- Fundamental
- Price
- CANF $1.20
- SNX $105.69
- Analyst Decision
- CANF Strong Buy
- SNX Strong Buy
- Analyst Count
- CANF 2
- SNX 9
- Target Price
- CANF $14.00
- SNX $137.22
- AVG Volume (30 Days)
- CANF 413.8K
- SNX 1.8M
- Earning Date
- CANF 04-29-2025
- SNX 03-27-2025
- Dividend Yield
- CANF N/A
- SNX 1.67%
- EPS Growth
- CANF N/A
- SNX 16.43
- EPS
- CANF N/A
- SNX 8.00
- Revenue
- CANF $674,000.00
- SNX $59,008,890,000.00
- Revenue This Year
- CANF $461.72
- SNX $3.50
- Revenue Next Year
- CANF N/A
- SNX $4.67
- P/E Ratio
- CANF N/A
- SNX $13.21
- Revenue Growth
- CANF N/A
- SNX 4.62
- 52 Week Low
- CANF $1.22
- SNX $92.23
- 52 Week High
- CANF $4.69
- SNX $145.10
- Technical
- Relative Strength Index (RSI)
- CANF 37.12
- SNX 41.34
- Support Level
- CANF $1.22
- SNX $102.01
- Resistance Level
- CANF $1.82
- SNX $105.01
- Average True Range (ATR)
- CANF 0.13
- SNX 4.70
- MACD
- CANF -0.02
- SNX 1.08
- Stochastic Oscillator
- CANF 3.13
- SNX 79.18
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).